Relapsing Multiple Sclerosis (RMS) Terminated Phase 4 Trials for Natalizumab (DB00108)

Also known as: Multiple Sclerosis Relapse / Relapsed Multiple sclerosis / Relapsing Multiple Sclerosis / Multiple sclerosis flare

IndicationStatusPhase
DBCOND0044896 (Relapsing Multiple Sclerosis (RMS))Terminated4
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02241785Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis (MS) After Failure on Other TherapiesTreatment